Merck KGaA and Pfizer enter second deal for avelumab combo research, now with Transgene

12 October 2016

Hot on the heels of an agreement to trial oncology drug candidate avelumab with the USA’s Vaccinex in lung cancer, German’s Merck KGaA (MRK: DE) and its partner Pfizer (NYSE: PFE) have now joined forces with French biotech firm Transgene (Euronext: TNG) for a study with the latter’s TG4001 in head and neck cancer.

Specifically, Transgene will sponsor a Phase I/II study evaluating the potential of the therapeutic vaccine candidate TG4001 in combination with avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, for the treatment of human papilloma virus- (HPV-) positive head and neck squamous cell carcinoma (HNSCC), after failure of standard therapy. Financial terms of the accord were not disclosed.

Avelumab is being developed by Merck under a collaboration with Pfizer through an alliance signed in 2014 that could generate up to $2.85 billion for the German firm.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK